Luminex Corporation (LMNX) Scheduled to Post Earnings on Monday
Luminex Corporation (NASDAQ:LMNX) will release its earnings data after the market closes on Monday, October 30th. Analysts expect Luminex Corporation to post earnings of $0.03 per share for the quarter.
Luminex Corporation (NASDAQ:LMNX) last issued its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.09 by $0.11. Luminex Corporation had a return on equity of 4.81% and a net margin of 4.72%. The business had revenue of $76.50 million for the quarter, compared to the consensus estimate of $75.45 million. During the same period in the prior year, the business earned $0.33 earnings per share. The business’s revenue was up 19.2% on a year-over-year basis. On average, analysts expect Luminex Corporation to post $0.53 EPS for the current fiscal year and $0.67 EPS for the next fiscal year.
Shares of Luminex Corporation (NASDAQ LMNX) traded down 0.24% during mid-day trading on Monday, hitting $20.41. The stock had a trading volume of 14,473 shares. Luminex Corporation has a 12-month low of $17.64 and a 12-month high of $22.27. The company has a 50 day moving average price of $20.07 and a 200 day moving average price of $20.05. The firm has a market cap of $899.49 million, a P/E ratio of 63.19 and a beta of 0.29.
The firm also recently declared a quarterly dividend, which was paid on Friday, October 13th. Stockholders of record on Friday, September 22nd were issued a dividend of $0.06 per share. The ex-dividend date of this dividend was Thursday, September 21st. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.17%. Luminex Corporation’s dividend payout ratio is 75.00%.
In other news, Director Robert J. Cresci sold 19,631 shares of the stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $18.98, for a total value of $372,596.38. Following the transaction, the director now owns 260,358 shares of the company’s stock, valued at approximately $4,941,594.84. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 6.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Luminex Corporation (LMNX) Scheduled to Post Earnings on Monday” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/23/luminex-corporation-lmnx-scheduled-to-post-earnings-on-monday.html.
A number of brokerages have recently weighed in on LMNX. ValuEngine upgraded Luminex Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Zacks Investment Research upgraded Luminex Corporation from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a report on Monday, July 17th. BidaskClub downgraded Luminex Corporation from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. TheStreet downgraded Luminex Corporation from a “b” rating to a “c+” rating in a report on Monday, August 7th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $21.00 price target on shares of Luminex Corporation in a report on Friday. Two analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $20.00.
Luminex Corporation Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.